Guanhao Biotech Co., Ltd.
2026 Annual Report on the Analysis of the Issuance Plan for Issuing Shares to Specific Objects Under a Simplified Procedure (Revised Draft)
Guanhao Biotech Co., Ltd. (hereinafter referred to as "Guanhao Biotech" or "the Company") is a company listed on the Growth Enterprise Market of the Shenzhen Stock Exchange. To meet the Company's capital needs for business development, enhance its capital strength, and improve profitability, in accordance with the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), the "Securities Law of the People's Republic of China" (hereinafter referred to as the "Securities Law"), the "Administrative Measures for the Registration of Issuance of Shares by Listed Companies" (hereinafter referred to as the "Registration Measures"), and the "Opinions on the Application of Securities Laws and Regulations in the Application of Articles 9, 10, 11, 13, 40, 57, and 60 of the Administrative Measures for the Registration of Issuance of Shares by Listed Companies — Securities and Futures Legal Application Opinion No. 18" (hereinafter referred to as the "Securities and Futures Legal Application Opinion No. 18"), and other relevant laws, regulations, and normative documents, the Company plans to issue shares to specific objects to raise RMB 97,499,995.74. The total amount raised shall not exceed RMB 300 million, which is no more than 20% of the Company's net assets at the end of the most recent fiscal year. The net proceeds from this fundraising, after deducting issuance expenses, are intended to be invested in the following projects:
| No. | Project Name | Total Project Investment (RMB million) | Proposed Amount of Raised Funds to be Invested (RMB million) |
|---|---|---|---|
| 1 | Industrialization Project for Biological Dura Mater Repair Material (Third-Generation Dura Mater Patch) | 7,363.12 | 6,825.00 |
| 2 | Supplement Working Capital and Repay Bank Loans | 2,925.00 | 2,925.00 |
| Total | 10,288.12 | 9,750.00 |
(Unless otherwise specified, terms used in this report have the same meaning as in the "Revised Draft of the 2026 Plan for Issuing Shares to Specific Objects by Guanhhao Biotech Co., Ltd.")
Chapter 1: Background and Objectives of This Issuance of Shares to Specific Objects
I. Background of This Issuance
(I) National Strategy Supports High-Quality Development of Regenerative Medicine
In recent years, the state has attached great importance to the development of frontier fields such as regenerative medicine and high-end medical implants. A series of policy documents, including the "Healthy China 2030 Planning Outline" and the "Opinions of the General Office of the State Council on Comprehensively Deepening the Reform of Drug and Medical Device Regulation to Promote the High-Quality Development of the Pharmaceutical Industry," have been issued. These policies provide strong policy support for the industry's development through various aspects such as R&D innovation support, accelerated review and approval, optimized medical insurance access, and improved centralized procurement rules.
Since 2025, the State Council has issued the "Administrative Provisions on Clinical Research and Clinical Transformation of New Biomedical Technologies," establishing a clear development framework, direction, and implementation path for the industrialization of cutting-edge technologies such as regenerative medicine materials. At the same time, policies supporting innovation in medical devices continue to increase, encouraging the independent R&D of high-end medical implants, biomaterials, and tissue engineering products, and promoting the upgrading of domestic innovation and industry.